BARTH SYNDROME: Elamipretide (MTP-131) improves physical fitness in people with Barth syndrome , as compared to the natural course of the disease, according to a new comparison using data from the Phase 2/3 TAZPOWER clinical trial. Stealth BioTherapeutics , the company that is developing elamipretide and which funded TAZPOWER, plans to […]
Click here to view original web page at mitochondrialdiseasenews.com